Literature DB >> 30251128

Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence.

Santiago Muñoz-Fernández1, Teresa Otón-Sánchez2, Loreto Carmona3, Jaime Calvo-Alén4, Alejandro Escudero5, Javier Narváez6, Jose Manuel Rodríguez Heredia7, Susana Romero Yuste8, Paloma Vela9, Sara Luján Valdés10, Ana Royo García10, José Luis Baquero11.   

Abstract

The aim of the study is to benchmark the use and attributed importance of well-established prognostic factors in rheumatoid arthritis (RA) in daily clinical practice, and to contrast the use of factors with their ability to predict outcome. Medline was searched (inception-Sep. 2016) for systematic reviews on factors predicting death, disability, structural damage or remission in RA. All factors identified were compiled in a matrix of factors × outcomes, and scoping reviews for each cell were then performed. A survey to 42 rheumatologists randomly selected explored the use of the list of prognostic factors and inquired about the perceived strength of association with poor prognosis. In a second round, participants were exposed to evidence from the matrix and to responses from other participants. Change on perceived strength of association was evaluated. Rheumatologists report using prognostic factors in clinical practice on a daily basis. Very young onset, joint counts at diagnosis, rheumatoid factor, ACPA, and radiographic erosions are used frequently and correctly recognized as strong predictors. Comorbidities and other associated problems, such as obesity, low bone mineral density, cardiovascular disease, or extra-articular manifestations, are perceived as moderately associated to prognosis but, nevertheless, rheumatologists also use them profusely. Genetic and other biomarkers and osteitis by magnetic resonance are less accessible in daily practice and they obtained better results on second round (probably after knowing the strength of association with prognosis). Rheumatologists use widely most prognostic factors with a strong predictive value. However, factors with low evidence of prognostic value are also used and some factors are not used despite good evidence.

Entities:  

Keywords:  Clinical medicine; Evidence-based practice; Prognosis; Rheumatoid arthritis; Systematic review

Mesh:

Year:  2018        PMID: 30251128     DOI: 10.1007/s00296-018-4152-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy.

Authors:  K G Shojania; L A Bero
Journal:  Eff Clin Pract       Date:  2001 Jul-Aug

Review 2.  Novel treatment strategies in rheumatoid arthritis.

Authors:  Gerd R Burmester; Janet E Pope
Journal:  Lancet       Date:  2017-06-10       Impact factor: 79.321

3.  Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study.

Authors:  Esther Toledano; Ana M Ortiz; Jose Ivorra-Cortes; Nuria Montes; Amada Beltran; Luis Rodríguez-Rodriguez; Loreto Carmona; Isidoro González-Álvaro
Journal:  Clin Exp Rheumatol       Date:  2017-11-28       Impact factor: 4.473

4.  [Are useful prognostic factors in rheumatoid arthritis?].

Authors:  Montserrat Robustillo Villarino; Jesús Rodríguez Moreno
Journal:  Reumatol Clin       Date:  2011-02-26

5.  Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.

Authors:  Maria Karolina Jonsson; Nina Paulshus Sundlisæter; Hilde Haugedal Nordal; Hilde Berner Hammer; Anna-Birgitte Aga; Inge Christoffer Olsen; Karl Albert Brokstad; Désirée van der Heijde; Tore K Kvien; Bjørg-Tilde Svanes Fevang; Siri Lillegraven; Espen A Haavardsholm
Journal:  Ann Rheum Dis       Date:  2017-08-16       Impact factor: 19.103

6.  Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke.

Authors:  Henrik Källberg; Bo Ding; Leonid Padyukov; Camilla Bengtsson; Johan Rönnelid; Lars Klareskog; Lars Alfredsson
Journal:  Ann Rheum Dis       Date:  2010-12-13       Impact factor: 19.103

7.  The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.

Authors:  Louise M A Jansen; Dirkjan van Schaardenburg; Irene van der Horst-Bruinsma; Rob J van der Stadt; Margret H M T de Koning; Ben A C Dijkmans
Journal:  J Rheumatol       Date:  2003-08       Impact factor: 4.666

8.  Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis.

Authors:  L H D van Tuyl; A M C Plass; W F Lems; A E Voskuyl; P J S M Kerstens; B A C Dijkmans; M Boers
Journal:  Rheumatology (Oxford)       Date:  2008-08-18       Impact factor: 7.580

9.  Bone mineral density in the hand as a predictor for mortality in patients with rheumatoid arthritis.

Authors:  Christina Book; Jakob Algulin; Jan-Ake Nilsson; Tore Saxne; Lennart Jacobsson
Journal:  Rheumatology (Oxford)       Date:  2009-06-24       Impact factor: 7.580

10.  Body Mass Index and Risk of Rheumatoid Arthritis: A Meta-Analysis of Observational Studies.

Authors:  Jian Feng; Qi Chen; Feifei Yu; Zhiyong Wang; Shuqi Chen; Zhichao Jin; Qing Cai; Yu Liu; Jia He
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more
  1 in total

1.  Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis.

Authors:  Goitybell Martínez; Eugen Feist; Maité Martiatu; Hilda Garay; Bárbara Torres
Journal:  Rheumatol Int       Date:  2020-05-29       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.